 CURRICULUM VITAE

**Magali J. Fontaine, M.D., Ph.D.**

Associate Professor, Department of Pathology

University of Maryland School of Medicine

**Date** 08/05/2016

**Contact Information**

Business Address: University of Maryland Medical Center

Department of Pathology

 22 South Greene Street, Room N2W50A

 Baltimore, MD 21201

Office Phone Number: 410.328.3834

Fax: 443.462.3248

Email: mfontaine@som.umaryland.edu

Foreign Languages: Fluent in English and French

**Education**

1981 Lycee Hoche-Versailles, BA (Baccalaureate)

###  1989 University René Descartes Paris, Cochin Port-Royal Medical School, MD

###  2000 University of Illinois at Chicago, Ph.D. in Transplant Pathology

**Post Graduate Education and Training**

###### 1990 - 1991 Surgical Research Fellow, Oncology Division

######  Adoptive Immunotherapy Using Tumor Infiltrating Lymphocytes

######  Brigham & Women's Hospital, Boston, Harvard Medical School

###### 1991 - 1993 Surgical Research Fellow, Transplantation Division, Tissue Engineering,

######  The Children's Hospital, Boston, Harvard Medical School

###### 1993 - 1994Internship in General Surgery, University of Illinois, Chicago

1994 - 1995 PGY II in General Surgery

 Metropolitan Group Hospitals Residency, Chicago

1995 - 1999 Residency in Pathology (AP, CP)

 University of Illinois College of Medicine

1999 - 2000 Fellowship in Transfusion Medicine, Mayo Clinic, Rochester

**Certifications**

1991 ECFMG Certificate

 FLEX

2001 Clinical Pathology

2002 Transfusion Medicine

**Medical Licensures**

State of Maryland (**active**) State of South Carolina (*inactive*) State of Minnesota (*inactive*)

State of California (*inactive*) State of Illinois (*inactive*)

**Employment History**

**Academic Appointments**

1997 - 1999 Clinical Instructor, Department of Pathology

 College of Medicine, University of Illinois at Chicago

2000 - 2002 Clinical Instructor, Department of Pathology

2003 - 2004 Assistant Professor, Department of Pathology

 Medical University of South Carolina (MUSC)

2004 - 2013 Assistant Professor, Department of Pathology

 Stanford University School of Medicine

2013 - Present Associate Professor, Department of Pathology and Medicine

 University of Maryland School of Medicine

**Academic Affiliations**

2005 - 2013 Assistant Professor, Interdisciplinary Program in Immunology

 Stanford University

2007 - 2013 Associate Member, Stem Cell Institute, Stanford University, California

2009 - 2013 Associate Member, Stanford BioX

2013 - Present Member of the Center for Stem Cell Biology & Regenerative Medicine

 University of Maryland School of Medicine

**Administrative Positions**

2000 - 2003 Assistant Director, Transfusion Services, Medical University of South Carolina

2001 - 2004 Director of the Islet Cell Isolation Facility, Medical University of South Carolina

2002 - 2003 Acting Director, Blood Bank, Medical University of South Carolina

2002 - 2004 Director of Cryopreservation Laboratory/Tissue Bank, Medical University of South Carolina

2004 - 2013 Associate Director of the Transfusion Service, Stanford University

2004 - 2013 Assistant Director of the Stanford Blood Center, Stanford University

2005 - 2008 Director of Stanford Clinical Laboratory (Fremont)

2007 - 2013 Associate Director of the Stanford Transfusion Medicine Fellowship Program

2008 - 2013 Director for POCT at Stanford LPCH Special Care Nursery at Sequoia Hospital

2013 - 2013 Director for POCT at Stanford LPCH Special Care Nursery at Washington Hospital

2013 - Present Director of the Transfusion Service and Cellular Therapy Processing Laboratory, University of Maryland

Professional Society Memberships

 2000 - Present AABB Advancing Transfusion and Cellular Therapies Worldwide (formerly named: American Association of Blood Banks)

2000 - Present Cell Transplant Society

2000 - Present Association of Clinical Scientists

 2001 - Present American Society of Hematology

 2004 - Present California Blood Bank Society

2005 - Present International Society for Cellular Therapy

 2005 - Present American Transplantation Society

 2013 - Present International Pancreas and Islet Transplantation Association

**Honors and Awards**

1989 MD Degree, Summa Cum Laude

2008 Excellence in Teaching, Stanford University School of Medicine

2009 Faculty Mentor Award for Postdoctoral Fellows in Immunology, Stanford University

2010 Chair of National Committee on Standards for Cellular Therapies American Association of Blood Banks (AABB)

2010 Stanford Leadership Development Program (nominated)

2011 President of the Association of Clinical Scientists

2011 Excellence in Teaching, Stanford University School of Medicine

2012 Stanford Leadership Development Advanced Program (nominated)

**Clinical Activities**

* Daily rounds with the Clinical Pathology Residents and Transfusion/Hematology Fellows to Review Blood Product Inventories, Transfusion Special Needs (i.e. Irradiated or CMV-free Blood Products), Transfusion Reactions, and Difficult Serologic Work ups.
* Transfusion Service Call Coverage on Average 2 weeks per month.
* Implement Innovative New Tests, Procedures and Approaches to Improve Patient Blood Management, Transfusion Safety and Blood Inventory Management.

**Administrative Service**

**Committees UMMC/UMB**

2013-Present UMMC Trauma Resuscitation Unit Committee, Member

2013-Present UMMC Pathology Residency Committee, Member

2013-Present University of Maryland Medical Center (UMMC) Transfusion Practice Committee, Member

2013-Present UMMC Pathology Residency Annual Program Committee, Member

2014-Present University of Maryland School of Medicine MD Ph.D. Program Advisory Committee, Member

2014-Present UMMC Cell Processing QA and Operation Committee, Chair

2015-Present University of Maryland School of Medicine GMP Facility Planning Committee, Member

2015-Present UMMC Patient Blood Management Committee, Co-Chair

**Committee Activities (previous)**

1. - 2004 Bone Marrow Transplant Committee-MUSC
2. - 2004 Liver Transplant Committee-MUSC
3. - 2004 Blood Utilization Committee-MUSC
4. - 2004 Pancreatic Islet Transplant Committee-MUSC
5. - 2004 Pathology Resident Selection Committee-MUSC

2002 - 2004 Associate Member at the College of Graduate Studies-MUSC

2004 - 2013 Blood Utilization Committee Stanford Hospital and Clinics and LPCH

2005 - 2013 Transfusion Education Committee, Chair

2006 - 2013 Critical Care Committee Stanford Hospital and LPCH

2008 - 2013 Point of Care Testing Committee

2008 - 2013 Stanford Immunology Program Postdoctoral Committee

2008 - 2013 Stanford Institute for Immunity Transplantation and Infection, Member

2010 - 2013 Stanford Institute for Stem Cell Biology and Regenerative Medicine Associate Member

2011 - 2013 Bio-X Stanford University, Affiliated Faculty

Local & National Service

**National**

2004-PresentVice-Chair of **Clinical Molecular Biology & Genetics Scientific Session Committee for the Association of Clinical Scientists**

**2005 - 2007** California Blood Banks Society for Safety and Compliance Committee

10/2005 JDRF task force on “Characterization of Pancreata from Islet Autoantibody positive cadaver donors”, Bethesda, Maryland

11/2007 Chair Organizer, Stanford Immunology Program at Asilomar

06/2008 AABB Working Group for developing comments to the FDA on the draft guidance on allogeneic pancreatic islet cell products.

2009-Present Member, AABB Cellular Therapy Section on Novel Therapies and Regenerative Medicine

2010-Present Member, AABB Subcommittee for the Evaluation of International Variances

2010 - 2013 Chair, Committee of the AABB Standards for Cellular Therapies

2011 - 2013 Chair, California Blood Bank Society Scientific Committee

2013-Present AABB Co-Chair, Novel Cell Therapies and Product Development Subsection

2013-2014 Member, American Society of Hematology Scientific Abstract Review Committee

2013-Present Board Member, California Blood Bank Society

2014-Present Member, AABB Cell Therapies Assessment Tool Committee

2014-Present Member, AABB Nominating Committee

2014-Present Chair, AABB Cell Therapy Education Program Unit

2014-Present Associate Scientific Member Best Collaborative

2015-Present Member, AABB Scientific Abstract Review Committee

2015-Present Member, AABB Scientific Program Committee

2015-Present Member, American Board of Pathology Test Development and Advisory Committee for Transfusion Medicine and Cellular therapies

**Editorial Boards**

2000-Present *Annals of Clinical and Laboratory Science*

2005 - 2008 *California Blood Bank Society (CBBS) Publications*

2005-Present *International Journal of Medical Science*

2012-Present *Journal of Blood Disorders and Transfusion*

2013-Present *Transfusion Medicine Reviews*

**Invitation for Peer-Review**

* *Blood Coagulation and Fibrinolysis*
* *Haematologica*
* *Journal of Perinatology*
* *Cancer*
* *Journal Expert Opinion on Pharmacotherapy*
* *Lancet*
* *Vox Sanguinis*
* *Transfusion*
* *Transfusion Medicine Reviews*

**Teaching** **Service**

**Graduate Students**

*Basic Sciences (45-100 students)*

## 1998 University of Illinois at Chicago, Experimental Pathology Course,

##  “Cell Transplantation and Tissue Engineering” (2 hours)

2000 Mayo Graduate Medical School

 “Blood Component Therapy” (2 hours)

2001 - 2002 MUSC / Medical Student Second Year Curriculum

 “Basic Hematology” (2 hours)

2005 – 2013 Stanford Human Health and Disease (1 hour Lecture; Three 2 hour lab)

 “Immunohematology”

2008 – 2013 Stanford Immunology 205 (2 hour Lectures)

 “Inflammation”

 “HIV”

 “Complement System”

2008 – 2013 Stanford Developmental Biology 296 (1 hour Lecture)

 “Replacement Cell Therapies for Type 1 Diabetes”

2013 – 2014 University of Maryland School of Medicine

 “Hematology Coagulation” (2 hours)

 “Hemolytic Anemias” (2 hours)

2015 – Present University of Maryland School of Medicine

 “Overview of Immunology” (2 hours)

**Clinical Pathology Residents and Fellows Lecture Series (2004-Present)**

*Clinical Sciences (30-100 trainees)*

* Immunohematology
* Therapeutic Apheresis
* Transfusion Reactions
* Hemolytic Disease of the Newborn
* Polyagglutination
* TRALI
* Quality Systems Essentials
* Lookbacks
* Platelet Refractoriness
* Immune-based and Regenerative Cellular Therapies

**Blood Management Lecture Series at the University of Maryland Medical Center (UMMC)**

*Clinical Sciences for Surgical and Medicine Residents*

May 2014 Patient Blood Management Symposium

2014-Present Introduction to Safety and Management of Blood Transfusion (Lectures to incoming interns, physicians and nursing staff in each department, 10 lectures per year)

**Undergraduate and Post-Baccalaureate Student Research Mentor**

Tom Chung (Summer 2007)

Jennifer Paige (Summer 2008)

Caitlin Rugg (2009-2011)

Diana Hamilton (2011-2013)

Alan Le (2011-2013)

Richard Schubert (2011-2013)

Hank Shi (2012-2015)

Hong Pang (2015-2016)

Navid Ashari (2016-Present)

**Medical Student Summer Research Program SPORT (NIDDK) at University of Maryland**

Jessica Johnson (Summer 2016)

**Graduate Student Research Committee Member**

Ratna Prasad, Ph.D. (Dept. of Neurology 2003, MUSC, Charleston, SC)

Ramandeep Rattan, (Dept. of Neurology 2003, MUSC, Charleston, SC)

Liese Biesen-Rothkopf (Dept. of Bioengineering 2010, Northwestern University, Evanston, IL)

Thomas Chung (Dept. of Management Science and Engineering 2010, Stanford, CA)

Jeffrey Kleinberger (Dept. of Medicine, University of Maryland, Baltimore, MD)

**Postdoctoral Fellow Mentor**

* Manana Kvezereli M.D. (2005-2009)

Awarded Stanford Dean’s Fellowship (05/01/2006-04/30/2007)

* Nicolynn Davis Ph.D. (2009-Present)

Awarded Stanford Immunology Program Training Grant (09/01/2009-08/31/2010)

**Transfusion Medicine Fellow Mentor**

Anthony Chen D.O. (2007-2008) Board Certified in 2008

Jenny Kuo M.D. (2008-2009) Board Certified in 2009

Juliana Gaitan M.D. (2008-2009) Board Certification Pending

Nicholas Ree M.D. (2009-2010) Board Certified

Susan Weiss M.D. (2010-2011) Board Certified in 2011

Lisa Pate M.D. (2011-2012) Board Certification pending

Jennifer Andrews M.D. (2011-2012) Board Certified in 2012

Jonathan Hughes M.D. (2012-2013) Board Certified in 2013

Janet McNaughton M.D. (2012-2013) Board certified in 2014

Tho Pham M.D. (2013-2014) Board Certified in 2015

Samantha Gomez (2013-2014) Board Certified in 2015

##### **Grants and Awards**

**Active Grants**

07/2016 - 06/2017 (PI, 5%)

 *“Silk-based encapsulation system to improved pancreatic islet function”*

 Living Legacy Foundation of Maryland Grant Program

 The goal of this study is to develop an islet cell *in vivo* delivery platform using silk-based biomaterial to enhance islet cell engraftment.

 Total Direct Costs: $60,000

07/2016 - 06/2019 (PI, 7%)

*“PIPER Study”*

Cerus Corporation

A Prospective, Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components.

 Total Direct Costs: $280,000

**Completed Grants**

1998 - 2000 (Co-Investigator) PI: Benedetti

#####  Warren and Clara Cole Foundation Grant Award

#####  University of Illinois at Chicago

 *“Islet Cell transplantation in the gastric mucosa of mongrel dogs”*

2002 - 2004 (PI)

MUSC Research Committee for Institutional Support

*“Improving survival of pancreatic cells for transplantation”*

2002 - 2004 (Co-Investigator)

 V.I. Technologies, Inc. (VITEX)

A phase III study to evaluate Pen 110-0101-treated red blood cells in chronically transfused patients

2003 - 2004 (Co-Investigator) PI: Kex

Merck, Inc.

Preventing Diabetes in NOD mice using the drug statin

2003 - 2008 (Principal Investigator)

Stanford University

 *“Preserving islet cell mass and function”*

2006 - 2007 (PI)

Stanford University School of Medicine

Dean`s postdoctoral fellowship for postdoctoral fellow Manana Kvezereli

 “*Protective Role of TNF-Alpha Stimulating Gene 6 in Pancreatic Islets”*

 The goal of this study is to characterize the expression and the anti-inflammatory role of TSG-6 in pancreatic islets during the onset of type 1 diabetes.

* 1. (PI)

Kai Pharmaceutical

*“PKC Epsilon activation to improve pancreatic islet cell graft viability and function”*

* 1. (PI)

NIH- 5T32AI007290-25 - Stanford Immunology Program Training grant. Steinman

 Postdoctoral Fellow Nicolynn Davis Ph.D.

 *“A novel approach to pancreatic islet encapsulation”*

11/2010 - 10/2014 (Co-Investigator, 5%) PI: Butcher

A Novel Tolerogenic Dendritic Cell: *“Biology & therapeutic potential”*

NIH - R01 DK084647-01A1

The goal of this study is to define the cellular and molecular mechanisms that novel tolerogenic dendritic cells employ to regulate T cell immunity; and to test their therapeutic potential in models of transplantation.

12/2010 - 6/2013 (PI, 2%)

 BIO-X Stanford Interdisciplinary Initiatives Program. *“Novel silk scaffolds for pancreatic islet encapsulation”* The goal of this study is to develop a novel scaffold to encapsulate islet cells for transplantation that will enhance cell survival and function and minimize immune-mediated destruction *in vivo*.

12/2010 - 11/2013 (Co-Investigator, 5%) PI: Shizuru

*“Purified allogeneic hematopoietic stem cells as a platform for tolerance induction”*

California Institute for Regenerative Medicine RFA0903

The goal of this study to develop conditioning regimens that will permit the safe translation of HSC transplants to induce tolerance to transplanted adult tissues and progenitor cells, and block the pathology of autoimmune disease.

2011 - 2013 (PI, 2%)

Sanofi Pharmaceutical

 *“Silk scaffolds for pancreatic islet encapsulation”*

2012 - 2013 (PI, 2%)

Children Research Institute (CHRI), Stanford, CA

 *“Preventing allergic transfusion reactions”*

The objective is to define peripheral blood markers, specifically on leukocytes (eosinophils, basophils, neutrophils), which are activated in chronically transfused patients presenting with recurrent allergic transfusion reactions.

2013 - 2014 (Co-Investigator, 2%) PI: Scalea

 *PROPPR*

PROPPR is a multicenter, randomized trial which will compare different ratios of blood products given to trauma patients who are predicted to require massive transfusions.

05/2014 - 04/2016 (PI, 4%)

 *“Controlled expansion of human mesenchymal stromal/stem cells by microRNAs to improve pancreatic islet function after transplantation”*

 Living Legacy Foundation of Maryland Grant Program

The goal of this study is to to identify miRs capable of promoting hMSC expansion and evaluate the immunoregulatory function of microRNA-expanded hMSCs in the context of islet transplantation to treat patients with T1D

06/2014 - 06/2015 (PI, 2%)

Enterprise Inc.

“*Portable point of care testing to assess coagulation in the field”*

In collaboration with Enterprise and U Maryland College Park, current instrumentation available for POCT coagulation testing such thromboelastogram (i.e. TEG versus ROTEM) is evaluated for development of more efficient and portable platforms.

**Publications**

**Peer-Reviewed Articles**

1. Rouffet F, **Fontaine MJ**, Zerbib JJ, Mathon C.#: Traitement chirurgical du cancer du colon gauche: Hemicolectomie ou colectomie segmentaire? - Surgical treatment of cancer of the left colon: True left hemicolectomy or segmental colectomy? *Journal de Chirurgie.* Paris 1988; (125):715-716
2. Mary P, Razafindrajao C, Colombu JP, **Fontaine MJ**, Rouffet F. Le cystadenocarcinome appendiculaire. Cystadenocarcinoma of the appendix. *Journal de Chirurgie*. Paris 1990; (127):298
3. **Fontaine MJ**, Hansen LK, Thompson S, Uyama S, Ingber DE, Langer R, Vacanti JP#. Transplantation of genetically altered hepatocytes using cell-polymer-constructs. *Transplantation Proceedings*. 1993; (25):1102-1104
4. **Fontaine MJ**, Schloo B, Jenkins R, Uyama S, Hansen L, Vacanti JP#. “Human hepatocyte transplantation using cell polymer constructs.” *Journal of Pediatric Surgery*. 1995; (30):56-60
5. Benedetti E, Kirby J, Asolati M, **Fontaine MJ**, Blanchard J, Ward MG, Hewitt T, Pollak R#. “Intrasplenic hepatocyte transplantation in Dalmatian dogs with and without cyclosporine immunosuppression.” *Transplantation* 1997; 15(63):1206
6. Benedetti E, Pollak R, Asolati M, **Fontaine MJ**, Mihalov M. “A prospective study on the predictive value of PCR assay for cytomegalovirus in asymptomatic kidney transplant recipients.” *Clinical Transplantation* 1998;12(5):391-395
7. Raofi V, **Fontaine MJ**, Mihalov M, Benedetti E#. Comparison of jejunal and ileal biopsies in a porcine model of intestinal transplantation. *Transplantation* 1999; 68:188-191
8. Raofi V, Holman DM, Dunn TB, **Fontaine MJ**, Mihalov M, Benedetti E. Comparison of rejection rate and functional outcome of small bowel transplantation alone or in conjunction with the ileocecal valve versus combined small and large bowel transplantation. *Clinical Transplantation 1999;* 13:389-394
9. **Fontaine MJ**, Homburger H, Nichols W#. Persistent problems with standardization of immunoassays for anti-cardiolipin antibodies. *Thrombosis Haemostasis* 2001; 86:1123-1124
10. **Fontaine MJ**, Blanchard J, Rastellini C, Lazda V, Herold K, Pollak R. Pancreatic islets activate portal vein endothelial cells in vitro. *Annals of Clinical and Laboratory Science* 2002; 32(4): 352-361
11. **Fontaine MJ**, Winters JL, Moore SB, McGregor CGA, Santrach PJ#. Frozen preoperative autologous blood donation for heart transplantation at the Mayo Clinic from 1988 to 1999. *Transfusion* 2003;43:476-480
12. **Fontaine MJ**, Fan W. Islet transplantation as a cure for insulin-dependent diabetes. *Hepatobiliary and Pancreatic Diseases International* 2003; 2(2):181-190
13. **Fontaine MJ**, Lazarchick J, Sarah Taylor, Annibale D. The use of recombinant factor VIIa in neonates with severe coagulopathy. *Journal of Perinatology* 2004; 24(5):310-311
14. [Marques RG](http://www.ncbi.nlm.nih.gov.laneproxy.stanford.edu/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Marques+RG%22%5BAuthor%5D), [**Fontaine MJ**](http://www.ncbi.nlm.nih.gov.laneproxy.stanford.edu/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Fontaine+MJ%22%5BAuthor%5D), [Rogers J](http://www.ncbi.nlm.nih.gov.laneproxy.stanford.edu/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Rogers+J%22%5BAuthor%5D). C-peptide: much more than a byproduct of insulin biosynthesis**.** *Pancreas* 2004; 29(3):231-238
15. **Fontaine MJ,** Malone J, Mullins F, Grumet K#. Diagnosis of transfusion-related acute lung injury (TRALI): TRALI or not TRALI? *Annals of Clinical and Laboratory Science* 2006; 2006 36: 53-58
16. **Fontaine MJ.** Safety of red blood cell additive solutions in neonatal patients. *CBBS Today* 2006; 24(1):29-33
17. Boyd SD, Stenard F, Goodnough LT, Esquivel C, **Fontaine MJ**. Alloimmunization to Red Blood Cell Antigens Affects Clinical Outcomes in Liver Transplant Patients *Liver Transplantation* 2007; 13(12):1654-61
18. Wong W, Merker J, Nguyen C, Berquist W, Viele M, Glader B, **Fontaine MJ.** Cold agglutinin syndrome associated with tacrolimus immunosuppression in pediatric liver transplant patients. *Pediatric Transplantation* 2007; 11(8):931-6
19. Burtelow M, Riley E, Druzin M, **Fontaine MJ**, Viele M, Goodnough LT. How we treat: Management of life-threatening primary postpartum hemorrhage using a standardized massive transfusion protocol. *Transfusion* 2007; 47(9):1564-72. *Participated in the conception and design of the protocol. Obtained material support for evidence based practice. Participated in drafting of the manuscript.*
20. KarnikSK, ChenH, McLeanGW, Heit JJ, GuX, ZhangAS, **FontaineMJ**, Yen MH and Kim SK#. Growth of maternal pancreatic ß-cells in pregnancy is controlled by menin. *Science* 2007; 318 (5851): 806 – 809. *Participated in the acquisition of data and in material support to obtain β-cells for the study. Participated in drafting and critical revision of the manuscript.*
21. **Fontaine MJ**. Strategies to prevent TRALI reactions. *CBBS Today* 2007; 25(3): 39-42.
22. KvezereliM, VallentinA, Mochly-RosenD, Busque S, **Fontaine MJ**. Islet cell survival improved during isolation through PKC epsilon activation. *Transplantation Proceedings* 2008*;* 40(2):375-378
23. Kvezereli M, Michie SA, Yu T, Creusot RJ, **Fontaine MJ**. TSG-6 protein expression in the pancreatic islets of NOD mice *Journal of Molecular Histology* 2008; 39(6):585-593
24. Padley D, Allickson J, Bollard C, Burns L, Creer M, Davis-Sproul J, **Fontaine MJ**, Hillberry CM, Linenberger, Linetsky E, Grable-McLeod M, Perlin T, Regan DM. Standards for Cellular Therapy Product Services. Third Edition. American Association of Blood Banks. 2008, Bethesda, MD. *Extensively participated in the analysis of public comments as well as the design, the drafting and the critical revision of the standards.*
25. Goodnough LT, Viele M, **Fontaine MJ**, JuradoC, Stone N, Quach P, ChuaL, Chin M, Scott R, Irina T, TabbK, Sharek PJ#. Implementation of a two specimen requirement for verification of ABO/Rh for blood transfusion. *Transfusion* 2009; 49(7):1321-1328 *Participated in the implementation of the procedure and in the acquisition/analysis of data. Greatly contributed to the drafting and revision of the manuscript*
26. **FontaineMJ**, ChungYT, RogersWM, SussmannHD, QuachP, GalelSA, Goodnough LT, and F Erhun. Improving Platelet Supply Chains through Collaborations between Blood Centers and Transfusion Services. *Transfusion* 2009; 49(10):2040-2047
27. Butwick A, Aleshi P, **Fontaine MJ\***, Riley E, Goodnough LT#. Retrospective analysis of transfusion outcomes in pregnant patients at a tertiary obstetric. Retrospective analysis of transfusion outcomes in pregnant patients at a tertiary obstetric. *International Journal of Obstetric Anesthesia* 2009; 18(4): 302-308. \**Collected and analyzed data. Took part in the drafting and revision of the manuscript.*
28. Padley D, Allickson J, Bollard C, Burns L, Creer M, Davis-Sproul J, **Fontaine MJ**, Hillberry CM, Linenberger, Linetsky E, Grable-McLeod M, Perlin T, Regan DM. Standards for Cellular Therapy Product Services. Fourth Edition. American Association of Blood Banks. 2010, Bethesda, MD. *Extensively participated in the analysis of public comments as well as the design, the drafting and the critical revision of the standards.*
29. **Fontaine MJ**. Immune Mediated hemolytic anemia in a pediatric patient two years after liver transplantation. *CBBS Today* 2010; 28(2): 39-41
30. **Fontaine MJ**, Jurado C, Miller E, Viele M, Goodnough LT#. Impact of CMV antibody reflex testing on management of blood inventory for patients requiring CMV compatible blood. *Transfusion* 2010; 50(8):1685-1689
31. **Fontaine MJ**, Chung YT, Erhun F,Goodnough LT#. Age of blood as a limitation for transfusion: Potential impact on blood inventory and availability. *Transfusion* 2010; 50(10):2233-9
32. Goodnough LT, Viele M, **Fontaine MJ**, Chua L, Ferrer Z, Jurado C, Quach P, Dunlap M, and Arber DA#. Quality Management in the Transfusion Service: Case Studies in Process Improvement. *Transfusion 2011; 51* (3):600-9. *Greatly Participated in the acquisition of data. Took part in the drafting and revision of the manuscript.*
33. Goodnough LT, Daniels K, Wong AE, Viele M, **Fontaine MJ**, Butwick AJ#. [How we treat: transfusion medicine support of obstetric services.](http://www.ncbi.nlm.nih.gov.laneproxy.stanford.edu/pubmed/21542850) *Transfusion* 2011; 51(12):2540-8. Collected data and *Took part in the conception and design of the process. Contributed to the critical review of the manuscript.*
34. NT Bleakly, **MJ Fontaine**, LL. Pate, S. Sutherland, M Jeng#. Disseminated Intravascular Coagulation due to IgM-Mediated Autoimmune Hemolytic Anemia in a Child. *Pediatric Blood and Cancer* 2011; 57 (2):329-31. *Extensively participated in the acquisition and analysis of data. Greatly contributed to the drafting and revision of the manuscript.*
35. **Fontaine MJ**, Chung YT, Erhun F, LT Goodnough. Response to “Modeling the effect of reducing maximum shelf life on RBC Availability”. *Transfusion* 2011;51(3):662
36. **Fontaine MJ**, Kuo JK, Miller E, Chen Ge, Vayntrub T, Galel S, Viele M, Goodnough LT, Tyan D. Complement fixing solid phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients. *Transfusion* 2011;51(12):2611-8
37. Atkinson MP, **Fontaine MJ**, Goodnough LT. A Novel Allocation Strategy for Blood Transfusions: Investigating the Tradeoff between the Age and Availability of Transfused Blood. Wein LM. Transfusion 2012; 52(1):108-17. *Extensively participated in the conception and design and in the acquisition of data. Contributed in critical revisions of the manuscript.*
38. **Fontaine MJ**, Mills AM, Weiss S, HongWJ, FerrerZ, DunlapM, GonzalezC, VieleM, GoodnoughLT. Platelet Inventory Management to Reduce ABO Incompatible Plasma Following a Sentinel Event. *Transfusion* 2012; 52(10):2081-5
39. DavisNE, RothkopfLN, Mirsoian A, Kojic N, Kaplan D, BarronAE, **FontaineMJ**. Enhanced function of pancreatic islets co-encapsulated with ECM proteins and mesenchymal stromal cells in a silk scaffold. *Biomaterials* 2012. 33(28):6691-7
40. PateLL, MyersJ, PalmaJ, VieleM, GalelSA, FerrerZ,GonzalezCL, BenitzWE, GarrattyG and **FontaineMJ**. Anti-Ge3 Causes Late-Onset Hemolytic Disease of the Newborn: The Fourth Reported Case in Three Hispanic Families. Transfusion. 2013. 53(10):2152-2157
41. RothkopfLN, Karfeld-SulzerLS, ZhangX, Kissler H, MichieSA, KaufmanDB, **FontaineMJ** and Barron AE. Protein Polymer Hydrogels: Effects of Endotoxin on Biocompatibility. *Journal of Biomaterial Applications* 2013. 28(3):395-406
42. **Fontaine MJ**, Schubert R, Hughes J, Tirouvanziam R. Preventing allergic transfusion reactions. *Annals of clinical and laboratory Science* (in press)
43. Davis NE, Hamilton D, **Fontaine MJ**. Harnessing the immunomodulatory and tissue repair properties of mesenchymal stem cells to restore β-cell function. *Current Diabetes Reports* 2012. 12(5):612-22
44. Hughes J, Gonzalez C, Layon A, Galel S, **Fontaine MJ**. Transfusion Associated Hepatitis A Infection: A Case Report. *CBBS Today* 2013. 30(5):21-23
45. Beenken-Rothkopf LN, Karfeld-Sulzer LS, Davis NE, Forster R, Barron AE, **Fontaine MJ**. The Incorporation of Extracellular Matrix Proteins in Protein Polymer Hydrogels to Improve Encapsulated Beta-cell Function. *Annals of clinical and laboratory Science* 2013. 43(2):111-21
46. **Fontaine MJ**, Allickson J. Standards for Cellular therapy. Sixth edition. American Association of Blood Banks. 2013, Bethesda, MD
47. Hughes J, **Fontaine MJ**, Gonzalez C, Layon A, Galel S. Case Report of a Transfusion Associated Hepatitis A Infection. *Transfusion* 2014; 54 (9): 2202-2206
48. Hughes J, McNaughton J, Andrews J, George T, Bergeron C, Pyke-Grimm K, Galel S, Gonzalez C, Goodnough LT, **Fontaine MJ**. Infusion pump-mediated mechanical hemolysis in pediatric patients. *Annals of clinical and laboratory Science* 2015 Mar;45(2):140-7
49. Novak DJ, Bai Y, Cooke RK, Marques M, **Fontaine MJ**, Gottschall J, Carey P, Scanlan M, Feibig E, Shulman I, Nelson J, Flax S, Daniel-Johnson J, Callum J, Hess JR and the PROPPR Study Group. Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: the experience of the PROPPR trial centers. *Transfusion* 2015. 55(6):1331-9
50. Hamilton D, Rugg C, Davis N, Kvezereli M, Busque S and **Fontaine MJ.** Treatment with PKC epsilon agonist improves islet graft function in a syngeneic diabetic mouse transplant model. *Cell Transplantation* 2014. 23(7):913-919
51. Hamilton D, Shih H, Schubert RA, Michie SA, Kaplan D, **Fontaine MJ.** A silk-based encapsulation platform for pancreatic islet transplantation improves islet function *in vivo. Tissue Engineering and Regenerative Medicine.* (in press)
52. Yabu JM, **Fontaine MJ**. ABO-Incompatible Living Donor Kidney Transplantation without Post-Transplant Therapeutic Plasma Exchange. *Journal of Clinical Apheresis.* 2015. 30(6):340-6
53. **Fontaine MJ**, Webster J, Gomez S, Pham TD, Goodnough LT, Galel SA. How do I implement an automated screen for high-titer ABO antibody as an inventory management tool for ABO plasma-incompatible platelets? *Transfusion* 2015. 55(12):2783-9
54. **Fontaine MJ**, Shih H, Schaefer R, Pittenger M. Unraveling the mesenchymal stromal cells’ paracrine immunomodulatory effects. *Transfusion Medicine Review* 2016. 30(1):37-43
55. Peng Z, Pati S, **Fontaine MJ**, Kozar R. Lack of Species Specific Difference in Pulmonary Function When Using Mouse Versus Human Plasma in a Mouse Model of Hemorrhagic Shock. *Journal of Trauma.* 2016 (in press)

**Invited Publications (Letters, Chapters, Reviews and Editorials)**

1. **Fontaine MJ**, Lazarchick J, Maes LA, Spivey MA. Agglutination versus rouleaux. *American Society of Clinical Pathology Immunohematology Techsample* 2002. I(4):17-21
2. Spivey MA, **Fontaine MJ.** Transfusion management of a liver transplantation patient with multiple alloantibodies. *American Society of Clinical Pathology Immunohematology Techsample* 2003. I(4):17-22

## **Fontaine MJ***.* Processing pancreatic islets of langerhans in the laboratory – A review. *International Association of Pediatric Laboratory Medicine Newsletter*, July 2002.

1. Galel SA and **Fontaine MJ**, **Hazards of neonatal blood transfusion**. *NeoReviews* 2006; 7: e69 - e75
2. **Fontaine, MJ**, Goodnough LT. In: M. R. Nowrousian (Ed.); Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology - Scientific and Clinical Aspects of Anemia in Cancer. Second Edition. Chapter 25:663-6678. Springer, Wien New York 2007.
3. **Fontaine MJ**. In: Greer J. P. (Ed.); Transfusion Medicine - Wintrobe’s Clinical Hematology, Twelfth Edition. Lea & Febiger Philadelphia 2007.
4. **Fontaine MJ**, Richa E, Gotlib J, NEJM Knowledge+. Authored 6 questions in Transfusion Medicine for comprehensive lifelong learning product from NEJM Group 2013. (product in development)

**Peer Reviewed Abstracts**

1. **Fontaine MJ**, Thompson S, Hansen LK, Mulligan RC, Vacanti JP *Optimization studies on retroviral mediated gene transfer into rat hepatocytes: Implications for gene therapy*. Annual Meeting of the Society of University Surgeons Residents' Program, Cincinnati, Ohio, February 15, 1992.
2. **Fontaine MJ,** Hansen LK, Thompson S, Uyama S, Ingber DE, Mulligan R, Langer R, Vacanti JP *Transplantation of genetically altered hepatocytes using cell-polymer-constructs*. XIVth International Congress of the Transplantation Society in Paris, France, August 16-21, 1992.
3. **Fontaine MJ**, Schloo B, Jenkins R, Uyama S, Hansen L, Vacanti JP. *Human hepatocyte transplantation using cell polymer constructs*. American Pediatric Surgical Association, Hilton Head, South Carolina, May 1993.
4. Benedetti E, Kirby J, Blanchard J, Ward MG, Williams R, Hewitt T, **Fontaine MJ**, Pollak R. *A large animal model for hepatocyte transplantation preliminary results in dalmatian dogs.* American Society of Transplant Surgeons, Dallas, Texas, May 29-31, 1996.
5. Kirby J, Mihalov M, Benedetti E, Johnson MT, Mangen MS, **Fontaine MJ**, Pollak R. *The value of PCR for CMV in asymptomatic transplant patients in predicting current or future CMV disease*. American Society of Transplant Physicians, Dallas, Texas, May 26-29, 1996.
6. Benedetti E, Kirby J, Asolati M, **Fontaine MJ**, Blanchard J., Ward MG, Hewitt T, Pollak R. *Intrasplenic hepatocyte transplantation in dalmation dogs with and without cyclosporine*. International Congress of Cell Transplant Society, Miami, Florida, September 30-October 2, 1996.
7. Asolati M, Mihalov M, Johnson W, Mangen GW, **Fontaine MJ**, Bartholomew A, Kirby J, Pollak R *A prospective study of PCR for cytomegalovirus in asymptomatic kidney transplant recipients*. American Society of Transplant Physicians. Chicago, Illinois. May 10-14, 1997.
8. **Fontaine MJ**, Diaz JR, Gould NS, McCorquodale DJ, McCorquodale NM. *Trisomy 20 and sirenomelia*. American Society of Human Genetics, Baltimore, Maryland, October 28-Nov 1, 1997.
9. Diaz JR, **Fontaine MJ,** Gould NS, McCorquodale DJ, McCorquodale MM. *Partial trisomy 7q in a 22 week fetus*. American Society of Human Genetics, Baltimore, Maryland, October 28-Nov 1, 1997.
10. Mihalov M, Asolati M, Johnson W, Mangen GW, **Fontaine MJ**, Bartholomew A, Kirby J, Pollak R. *A prospective study of PCR for cytomegalovirus in asymptomatic kidney transplant recipients*. Association for Molecular Pathology, San Diego, California, November 12-15, 1997.
11. Holman D, Raofi V, Asolati M, Dunn T, **Fontaine MJ**, Mihalov M, Massad M, Vitello J, Benedetti E *Combined large bowel versus small bowel only transplant in a pre-clinical porcine model.* American Society of Transplant Physicians. Chicago, Illinois, May 1998.
12. Raofi V, **Fontaine MJ**, Mihalov M, Holman D, Asolati M, Dunn T, Massad M, Vitello J, Benedetti E *Comparison of jejunal and illeal biopsie in a porcine model of bowel transplantation*. World congress of the Transplantation Society. Montreal, Canada, August 1998.
13. **Fontaine MJ**, Blanchard J, Lazda V, Brandt J, Herold K, Pollak R *An in-vitro study of the activation of portal vein endothelial cells by pancreatic islets*. International Cell transplantation Society. Montreux, Switzerland, March 1999.
14. **Fontaine MJ**, Blanchard J, Lazda V, Brandt J, Herold K, Pollak R. *An in-vitro study of the activation of portal vein endothelial cells by pancreatic islets*. American Society of Transplant Physicians. Chicago, Illinois, May 1999.
15. **Fontaine MJ**, Gregory LJ, Nichols W, Homburger HA. *Comparative evaluation of three assays for anti-cardiolipin antibodies*. International symposium on antiphospholipid antibodies. Tours, France. September, 2000.
16. **Fontaine MJ,** Moore B, Santrach P. *Preoperative autologous blood donation for heart transplantation*. American Association of Blood Banks, Washington D.C., November 2000.
17. Yimenez T, Moore B, Degoey S, **Fontaine MJ**. *ATG, OKT3, and IGIV therapy and platelet crossmatching by solid phase red cell adherence*. American Association of Blood Banks, Washington D.C., November 2000.
18. Lewin J, Rogers J, Lin A, Baillie M, Baliga P, Maes LA, **Fontaine MJ**, Chavin K. *The role of plasmapheresis in severe coagulopathy and liver primary non-function*. American Society of Transplantation Annual Meeting, Washington D.C., April 2002.
19. Baston R, Brunson C, **Fontaine MJ**, Anderson J, Maes L. *Hemolytic transfusion reaction following red cell exchange due to passively transfused high-titer anti-D*. American Society for Apheresis Annual Meeting, Orlando Florida, May 2002.
20. Maes L, Baston R, Steed L, **Fontaine MJ.** *Platelet transfusion-related bacterial sepsis secondary to donor’s transient bacteremia*. American Society for Apheresis Annual Meeting, Orlando Florida, May 2002.
21. **Fontaine MJ**, Chavin K, Rogers, J, Lin A, Baliga P, Maes L. *Plasmapheresis in severe coagulopathy and primary graft non-function liver transplant patients*. American Society for Apheresis Annual Meeting, Orlando Florida, May 2002.
22. **Fontaine MJ**, Kraveka J, Barredo J, Abboud M, Maes L. *Leukopheresis in an infant presenting with neurologic and respiratory distress*. American Society for Apheresis Annual Meeting, Orlando Florida, May 2002.
23. **Fontaine MJ**, Rastellini C, Herold K, Pollak R. *Activation of the portal vein endothelium by pancreatic graft: In vitro study* Association of Clinical Scientists. Salt Lake City, Utah, May 2002.
24. Assoufid L, Vogt S, Legnini D, Maser J, **Fontaine MJ.** X-ray synchrotron radiation microprobe analysis of the beta-cell from the Islet of Langerhans. Association of Clinical Scientists, St Petersburg, Florida, May 2003.
25. **Fontaine MJ**, Papadea C, Singh I, Key L. *Improving pancreatic islet cell viability and function during the peri-transplant period*. Association of Clinical Scientists, St Petersburg, Florida, May 2003.
26. **Fontaine MJ**, Papadea C, Singh I, Pinder L, Key L. *Preconditioning pancreatic donor improves islet cell function in-vitro after isolation*. International Pancreas and islet Cell Transplantation Association, Dublin, Ireland, July 2003.
27. Taylor S, Annibale D, Lazarchick J*,* **Fontaine MJ**. *Recombinant Factor VIIa Corrects Coagulopathy in a Neonate with Necrotizing Enterocolitis and Tk-Cryptantigen Activation*. American Association of Blood Banks, San Diego, CA, November 2003.
28. **Fontaine MJ**, Malone J, Mullins F, Grumet C. *Diagnosis of transfusion-related acute lung injury (TRALI): TRALI or not TRALI?* Association of Clinical Scientists Annual Meeting, Troy, Michigan, May 2005.
29. Boyd SD, L.T. Goodnough LT, Viele M, Esquivel C, **Fontaine MJ**. *Transfusion Management of Liver Transplant Patients with Multiple Alloantibodies*. Society for the advancement of blood management, Phoenix, Arizona, September 2005.
30. Nguyen C, Wong W, Merker J, Berquist W, **Fontaine MJ** and Glader B. *Autoimmune hemolytic anemia in pediatric liver transplant patients on FK506.*  World Transplant Congress, Boston, Massachusetts, July 2006.
31. Boyd SD, Stenard F, Goodnough LT, Esquivel C, **Fontaine MJ**. *Alloimmunization to Red Blood Cell Antigens Affects Clinical Outcomes in Liver Transplant Patients*. American Association of Blood Banks, Miami, Florida, October 2006.
32. Wong W, Merker J, Nguyen C, Berquist W, Glader B, **Fontaine MJ**. *Cold Agglutinin Syndrome in Post-Liver Transplant Patients on Tacrolimus*. American Society of Hematology, Orlando, Florida, Blood, Volume 108(11) 2006.
33. Kvezereli M, Vallentin A, Mochly-Rosen D, Busque S, **Fontaine MJ.** *Islet cell survival during isolation improved through PKC epsilon activation*. CTS-IPITA-IXA 2007 Joint Conference**.** *Xenotransplantation* 14(5):516-517, 2007.
34. Rogers WM, Chung T, Sussmann H, Erhun F, **Fontaine MJ**. *Platelet Inventory Management: Optimizing Platelet Inventories through Collaborations with Blood Center, and Transfusion Services.* Society for the advancement of blood management Symposium 2007. Hollywood, California. *Transfusio*n 47(11): 11A-29A
35. **Fontaine MJ**, Jurado C, Miller E, Viele M, Goodnough LT. *Implementation of CMV reflex testing for patients requiring CMV compatible blood*. American Association of Blood Banks, Montreal, Canada. October 2008. *Transfusion* 48S:269A
36. Sussmann H, **Fontaine MJ**, Geary D, Quach P, Mebane W, Galel S, Erhun F. *Maximizing platelet inventory from a 6 days per week draw schedule with 5-day products based on supply chain approach*. American Association of Blood Banks, Montreal, Canada. October 2008. *Transfusion* 48S:263A
37. Kvezereli M, Wang D, Nicolls MR, **Fontaine MJ**. *Glycan expression profile in freshly isolated pancreatic islets*. 15th NAT – Beta cell replacement in diabetic patient, Nantes, France. June 2009.
38. **Fontaine MJ**, Kvezereli M, Creusot RJ, Michie SA *TSG-6 expression in the pancreatic islet.* 15th NAT – Beta cell replacement in diabetic patient. Nantes, France. June 2009.
39. Kuo J, Tyan D, Miller E, Chen G, Vayntrub T, Galel S, Viele M, **Fontaine MJ**. *Complement fixing solid phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients*. American Association of Blood Banks, New Orleans, Louisiana. October 2009. *Transfusion* 49(S3):149A
40. **Fontaine MJ**, Chung YT, Erhun F,Goodnough LT. *Age of blood as a limitation for transfusion: Potential impact on blood inventory and availability*.American society of hematology. New Orleans, Louisiana, December. *Blood* .2009;114(22):1220-21. **(Selected for Highlight of ASH 2009)**
41. Goodnough LT, VieleM, **FontaineMJ**, ChuaL, FerrerZ, JuradoC, QuachP, DunlapM, ArberDA. *Quality management for event discovery reporting in the transfusion service*. American Association of Blood Banks, Baltimore, Maryland. October 2010. *Transfusion 50* (S2):270A
42. Ree N, Pate L, Viele M, **Fontaine MJ**, Gonzalez C, Goodnough LT, Galel S*. Unexpected immune-mediated hydrops in infants of mothers with routine prenatal care*. American Association of Blood Banks, Baltimore, Maryland. October 2010. *Transfusion* 50(S2):120A
43. Pate LL, Myers J, Palma J, Ree N, Viele M, Galel SA, Ferrer Z,Gonzalez CL, Benitz W, **Fontaine MJ.** *Anti-Gerbich 3 causes late-onset hemolytic disease of the newborn: The fourth reported case in three Hispanic families*. American Association of Blood Banks, Baltimore, Maryland. October 2010. *Transfusion 50*(S2):116A
44. K Alimoghaddam, AC. Logan, R Wong, S Weiss, **MJ Fontaine**, S Arai, C Grumet, DB. Miklos**.** *Minor ABO mismatch is associated with increased non-relapse mortality after allogeneic hematopoietic cell transplantation.* American Society for blood and Marrow Transplantation, Honolulu, Hawaii, February 2011. *Biology of blood and bone marrow transplantation*. 17( 2) S308-S309
45. Weiss S, Mills A, Ferrer Z, Dunlap M, Gonzalez C, Viele M, Goodnough LT, **Fontaine MJ**. *Platelet Inventory Management to Reduce ABO Incompatible Plasma in Platelet Units.* Transfusion 2011;51(3S):59A
46. Mills A, Weiss S, Hong WJ, Ferrer Z, Gonzalez C, Viele M, Goodnough LT, **Fontaine MJ**. *Anti-A Mediated Intravascular Hemolysis with Platelet Transfusion Following ABO Incompatible Hematopoietic Stem Cell Transplantation (HCT)*. Transfusion 2011; 51(3S):154A
47. DavisNE, RothkopfLN, Mirsoian A, Kojic N, Kaplan D, BarronAE, **FontaineMJ *A novel platform for islet transplantation using silk hydrogels*.** Oral presentation at the *Cell Transplantation Society 2011 International Congress.* Miami, Florida, October 23-26, 2011.
48. Rugg C, Davis N, Kvezereli M, Busque S and **Fontaine MJ**. *Treatment with PKC epsilon agonist improves islet graft function in a syngeneic diabetic mouse transplant model*. Presented as a poster at the *Cell Transplantation Society 2011 International Congress.* Miami, Florida, October 23-26, 2011.
49. **Fontaine MJ**, Obukhanych T, Tirouvanziam R. *Preventing Transfusion Reactions.* Oral presentation at the 2012 Annual Meeting of the Association of Clinical Scientists. Mobile Alabama Annals of Clinical and Laboratory Science 2011, 42(2):224
50. Hamilton D, Yefimenko N, Allickson JA and **Fontaine MJ**. Growth characteristics and immunomodulatory properties of mesenchymal stem cells depend on the tissue of origin. *Transfusion* 2012, 52(3S):39A
51. **Fontaine MJ**, Webster J, Goodnough LT and Galel S. Automated screen for high titer Anti-A and anti-B and selective plasma volume reduction as an inventory management strategy of ABO plasma incompatible platelets. *Transfusion* 2012, 52(3S):39A
52. Hughes J, McNaughton J, Andrews J, George T, Bergeron C, Pyke-Grimm K, Galel S, Gonzalez C, Goodnough LT, **Fontaine MJ.** Hemoglobinuria and Mechanical Hemolysis Associated with Red Blood Cell Transfusion in Pediatric Patients. *Blood* 2012, 120 (21):3429 **(Selected for Highlight of ASH 2012)**
53. **Fontaine MJ.** The most significant changes in Transfusion Medicine: 2003-2013, *Annals of Clinical and Laboratory Science* 2014, 44:341-359
54. Ebrahimnejad A, Hunt J, Cooke R, **Fontaine MJ.** Inconclusive Red Blood Cell Antibody Identifications with Solid Phase versus Manual Methods. *Transfusion* 2014, 54 (S):177A
55. Dietrich R, Christenson R, Duh SH, **Fontaine MJ** Viscoelastic Coagulation Monitoring: Current use of TEG, ROTEM, and Sonoclot. Accepted for poster presentation at 2015 Annual meeting of AACC, Atlanta, Georgia. July 2015.
56. Parker L, Hunt J, **Fontaine MJ.** Expanding the use of type A Plasma in critical care patient resuscitation. Accepted for poster presentation at 2015 Annual Meeting of AABB, Anaheim, CA. October 2015.
57. Parker L, Hunt J, **Fontaine MJ.** Expanding the use of type A Plasma in critical care patient resuscitation. Accepted for poster presentation at 2015 Annual Meeting of AABB, Anaheim, CA. October 2015.
58. FusaroMV, NielsenND, NielsenA, **FontaineMJ**, HessJR, ReedRM, DeLisleS, Netzer G. Decision Model Assessing Effects of a Restrictive Transfusion Strategy on Transfusion-Associated Pulmonary Adverse Events Among Patients with Cardiovascular Disease Following Hip Surgery. Accepted for poster presentation at the 2016 American Thoracic Society International Conference, San Francisco, CA, May 2016.
59. Parimi N, Yang S, Hu P, Li H, Mackenzie CF, RA , **Fontaine MJ**, Miller C, Scalea TM, Stein DM. Emergency blood transfusion following trauma-Selecting the right patient. Accepted for poster presentation at the 2016 annual meeting of the Shock Society, Austin, TX, June 2016.

**Published Multimedia**

1. Interviewed for Blood Bank Guy Educational Pod Cast: BBGE 004: Dr. Magali Fontaine on Transfusion Service Choices by [Joe Chaffin](http://www.bbguy.org/author/joechaffin/), April 18, 2016.
2. AABB Cellular Therapy Certificate Program. <http://www.aabb.org/aabbcct/Pages/cellular-therapies-certificate-program.aspx>, launched August 1st, 2016.

Invited Lectures

02/1998 “*Pancreatic Islet Cell Transplantation*” Rush Presbyterian Hospital/Department of Pharmacology, Chicago, IL

01/1999 “*An in-vitro study of the activation of portal vein endothelial cells by pancreatic islets*” University of Illinois at Chicago, Graduate Student Forum Chicago, IL

03/2004 “*Transfusions: Life Saving or Life Threatening*?” Stanford University Medical Center Stanford, CA

07/2004 “*Transfusion Reactions*” San Jose State University Clinical Laboratory Scientist Training Program, San Jose, CA

08/2004 “*Optimization of islet cell function during isolation prior to transplantation*” Fifteenth International Symposium on Molecular Biology of Hematopoiesis, Tokyo, Japan

02/2005 “*The Bridge between Bench and Bedside: Transfusion Service Medical Director*” California Blood Bank Society Regional Seminar, Oakland, CA

05/2005 “*Diagnosis of transfusion-related acute lung injury*” Association of Clinical Scientists Annual Meeting, Troy, MI

05/2006 “*Islet cell transplantation as a cure for type I diabetes*” Stanford Immunology Program Seminar Series, Stanford, CA

09/2006 “*Protective role of TNF-stimulating gene 6 in pancreatic islets*” Third Georgian Congress of Allergology and Immunology, Tbilisi, Georgia

11/2006 “*Preservation of pancreatic islet cell mass for transplantation in patients with Type 1 Diabetes*” Northwestern University Pathology Research Conference, Chicago, IL

07/2007 “*Pathophysiology and Diagnosis of TRALI*” Midland Memorial Hospital Midland, Texas

05/2008 “*Optimizing platelet inventory management*” Association of Clinical Scientists Annual Meeting, Marina del Rey, CA

08/2008 “*Changes to the 3rd edition of Standards for Cellular Therapy Product Services*” AABB Audioconferences series, Bethesda, MD

09/2008 “*Advocating Blood-Management Strategies in the Surgical Patient*” Society for the Advancement of Blood Management Annual Meeting, Baltimore, MD

06/2009 “*Preservation of pancreatic islet cell mass in patients with type 1 diabetes*” University of New Castle, New Castle, United Kingdom

10/2009 “*The Ups and Downs of Fluid and Electrolyte Balance and Blood Therapy*” Stanford Hospital and Clinics Center for Education, Palo Alto, CA

02/2010 “*Changes to the 4th edition of Standards for Cellular Therapy Product Services*” AABB Audioconferences series, Bethesda, MD

04/2010 “*Cell therapies for type 1 diabetes*” Stanford University School of Medicine Department of Pathology Research Retreat Stanford, CA

05/2010 “Hemolytic Reactions in Pediatric Liver Transplant Patients” California Blood Bank Society Annual Meeting Orange, County, CA

05/2010 “*Glycan expression profile in freshly isolated pancreatic islets*” Annual Meeting of the Association of Clinical Scientists, San Antonio, TX

05/2010 “Ask the experts session” California Blood Bank Society Annual Meeting, Orange County, CA

10/2010 “*Ask the Standards Committee*” AABB Annual Meeting, Baltimore, MD

11/2010 “*Novel cell therapies for type 1 diabetes*” University of California San Diego, La Jolla, CA

12/2010 “*Novel strategies in blood inventory management*” Transfusion Medicine Grand Rounds, Children s Hospital/Harvard Medical School, Boston, MA

01/2011 “*Adverse Events in Blood Transfusions*” The French Institute for Blood Transfusion-Marseille-France, Marseille, France

08/2011 “*Changes to the 5th edition of Standards for Cellular Therapy Product Services*” AABB Audioconferences series, Bethesda, MD

10/2011 “*A novel platform for islet transplantation using silk hydrogel*” Cell Transplantation annual meeting, Miami, FL

10/2011 “*Evaluate and implement a plan for inventory management of ABO plasma incompatible platelets*” American Association of Blood Banks Annual meeting San Diego, CA

10/2011 “*Islet cell therapy in vivo monitoring*” American Association of Blood Banks, San Diego, CA

11/2011 “*Islet Cell and Other Somatic Cell Therapies”* AABB Audioconferences series, Bethesda, MD

04/2012 “*Hemolysis due to platelet apheresis ABO incompatible plasma*” California Blood Bank Society, San Francisco, CA

05/2012 “*Preventing allergic transfusion reactions*” Association of Clinical Scientists Annual Meeting, Mobile, AL

09/2012 “*Current Developments on blood inventory managements*” The Mount Sinai School of Medicine Department of Pathology Seminar Series, New York, NY

10/2012 “*Managing the Blood Supply, Should Old Blood Prove to be Bad Blood”* American Association of Blood Banks, Boston, MA

11/2012 “*Current Cell Therapy Developments for Type 1 Diabetes*” Pathology Grand rounds, University of Chicago, Chicago, IL

04/2013 “*C1q testing for HLA Ab screen in patients refractory to platelet transfusion*” California Blood Bank Society, Huntington Beach, CA

10/2013 “*A silk-based encapsulation platform for pancreatic islets reduces marginal mass for transplantation and improves islet function in vivo”* International pancreas and Islet Transplantation Association, Monterey CA

10/2013 “*Activation and Phenotypic Expression Profile of Peripheral Blood Leukocytes in Patients Presenting with Allergic Transfusion Reactions*” American Association of Blood Banks, Denver, CO

12/2013 “*The most significant changes in Transfusion Medicine: 2003-2013*” Anesthesia Grand rounds, University of Maryland Medical Center, Baltimore, MD

12/2013 “*Evaluate and implement a plan for inventory management of ABO plasma incompatible platelets*” American Red Cross Medical Advisory Council Meeting, Washington DC

05/2014 “*An Update in Transfusion medicine: 2003-2013*” Blood Bank Seminar. The National Institute of Health, Bethesda, MD

06/2014 “*The most significant changes in Transfusion Medicine: 2003-2013*” Key Note Speaker at the Annual meeting of the American Association of Clinical Scientists. Amelia Island, FL

09/2014 “*Silk-based encapsulation system for pancreatic islet delivery in vivo*” University of Maryland School of Medicine Council, Baltimore, MD

10/2014 “*Introduction to Regenerative and Immunomodulatory Capacity of Mesenchymal Stromal/Stem Cells: From the Bench to Clinical Practice*” American Association of Blood Banks, Philadelphia, PA

10/2014 “*Introduction to Engineered T-cell vaccine for cancer therapy*” American Association of Blood Banks, Philadelphia, PA

01/2015 “From immunotherapy to islet replacement therapy for type 1 diabetes**”** Endocrinology Grand Rounds, University of Maryland, Baltimore, MD

05/2015 “*The Most Significant Changes in Blood Banking in the Last 10 Years”* Department of Medical and Research Technology, University of Maryland School of Medicine, Baltimore, MD

10/2015 “*Young donor plasma versus stem cell therapies for neuro degenerative diseases*” American Association of Blood Banks, Anaheim, CA

04/2016 “*Infusion of Young Blood Donor Plasma to Reverse Age-Related Impairments in Brain Function*” California Blood Bank Society Annual Meeting 2016, San Diego, CA

06/2016 “*Adipose-Derived Stem Cell Banking for Reconstructive and Regenerative Medicine*” AABB Audioconferences series, Bethesda, MD